Bone Loss, Prostate Cancer
Conditions
Brief summary
Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.
Interventions
None listed
Sponsors
Lawson Health Research Institute Internal Review Fund
University of Western Ontario, Canada
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men * Age of 40 years or greater * Diagnosis of advanced prostate cancer (ie: prostate-specific antigen \[PSA\] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone \[LHRH\] therapy) * Willing and able to consent
Exclusion criteria
* Metastatic disease to bone * Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant) * Renal failure (serum creatinine \> 200 umol/L) * Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis) * Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty) * Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial * Gastrointestinal (GI) pathology (eg. malabsorption syndrome) * Parathyroid disease
Countries
Canada
Outcome results
None listed